Investigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
The clinical investigator and her colleagues sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.
Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.
Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Conclusion of the discussion and award presentation.
Conclusion of the discussion and award presentation.
Patients with locally advanced or metastatic EGFR-mutant nonsquamous non–small cell lung cancer who progressed on an EGFR inhibitor may benefit from treatment with sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy vs chemotherapy alone.
Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Experts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
“Even after doing 10,000 of these operations, we are tweaking [the hood technique]…to make things better,” according to Ash Tewari, MD, MBBS, MCh, FRCS.
Certain patients with RAS wild-type colorectal cancer should be treated with bevacizumab in place of cetuximab in combination with FOLFOXIRI.
Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
The panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.